Abstract:RATIONALE: TNFα plays an important role in inflammatory bowel disease (IBD), especially Crohn's disease. Blocking TNFα using mAb or soluble receptors has shown to be effective in the treatment of IBD. We have developed TNFα peptide-based vaccines which produce long-lasting autoantibodies to TNFα. Here, we explored the in vivo effects of the administration of a TNFα vaccine in the downregulation of bowel inflammatory responses using a mouse model of colitis, induced by trinitrobenzene sulfonic acid (TNBS), which reflects features of Crohn's disease. METHODS: Mice were subcutaneously immunized three times (2-week intervals) with a mouse TNFα vaccine or the vaccine carrier as control. One week after the final immunization, mice were intra-rectally administered with 2 mg of TNBS in 50% ethanol. Symptoms and body weight were monitored daily. On day 3, mice were sacrificed. Colon inflammation was evaluated by histological examination and myeloperoxidase (MPO) activity assay which reflects tissue inflammation. Serum TNFα specific-IgG was measured by ELISA. RESULTS: Vaccinated mice had significantly higher levels of TNFα-specific IgG, less body weight loss, and lower MPO activity compared with the carrier group. Colon tissues of vaccinated mice showed less infiltration of neutrophils and other features of inflammation than controls. Moreover, in another experiment where the dose of TNBS increased, 4 out of 6 mice died in the carrier group, while only one died in the vaccine group. CONCLUSIONS: Administration of TNFα vaccines induces autoantibodies to TNFα and improves colitis-induced symptoms and death, suggesting a therapeutic potential applicable to human IBD.

Prepared and screened a modified TNF-alpha molecule as TNF-alpha autovaccine to treat LPS induced endotoxic shock and TNF-alpha induced cachexia in mouse.

Development of a Recombinant Xenogeneic Tumor Necrosis Factor Alpha Protein Vaccine to Protect Mice from Experimental Colitis.

The Preventive Effect of Adjuvant-Free Administration of TNF-PADRE Autovaccine on Collagen-Ii-induced Rheumatoid Arthritis in Mice.

Development of A Recombinant Xenogeneic TNF-α Protein Vaccine to Protect Mice

A Single Codon Optimization Enhances Recombinant Human TNF-α Vaccine Expression in Escherichia Coli

Tumour Necrosis Factor Alpha (tnfα) Vaccines in the Downregulation of Bowel Inflammatory Responses in Mice

An engineered TNFR1-selective human lymphotoxin-alpha mutant delivered by an oncolytic adenovirus for tumor immunotherapy

Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity.

Relationship between anti-tumor necrosis factor -α monoclonal antibody and chronic colitis in mice.

A Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in Mice.

Preparation and identification of transmembrane TNF-α(TM-TNF-α)specific monoclonal antibody

Preparation and Characterization of a Fully Human Monoclonal Antibody Specific for Human Tumor Necrosis Factor Alpha

Preparation And Evaluation Of A New Releasable Pegylated Tumor Necrosis Factor-Alpha (Tnf-Alpha) Conjugate For Therapeutic Application

The Protective Antibodies Induced by a Novel Epitope of Human TNF-α Could Suppress the Development of Collagen-Induced Arthritis

Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb

Preparation and Evaluation of a New Releasable PEGylated Tumor Necrosis Factor-Α (Tnf-Α) Conjugate for Therapeutic Application

Study on Enhanced Immune Response by Immunization with Attenuated Activated Autologous T Cells

Vaccine targeting TNF epitope 1–14 do not suppress host defense against Mycobacterium bovis Bacillus Calmette-Guérin infection

Construction and Preliminary Investigation of a Plasmid Containing a Novel Immunotoxin DT390-IL-18 Gene for the Prevention of Murine Experimental Autoimmune Encephalomyelitis.

Development of a TNF-α-mediated Trojan Horse for bacteria-based cancer therapy

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α